早期集中苯二氮䓬治疗对重度酒精戒断综合征住院时间的影响
本研究为前后对照队列研究,在学术医疗中心纳入113例重度酒精戒断综合征患者(PRE组75例,POST组38例)。PRE组按RASS给予症状触发、递增剂量的地西泮和苯巴比妥;POST组采用限时方案:24小时负荷期内递增剂量苯二氮䓬和苯巴比妥,72小时减量期后全部停药,并用SHOT量表辅助RASS评估非激越症状。POST组接受集中治疗的比例更高(73.7% vs 51.3%,p=0.03),住院时间(9.8天 vs 14.0天,p=0.03)和ICU时间(4.4天 vs 7.4天,p=0.03)均显著缩短。作者认为早期集中管理重度酒精戒断综合征与ICU和住院时间缩短相关。
要点
- 重度酒精戒断综合征定义为需要地西泮剂量>30 mg的患者。
- 集中治疗定义为在识别酒精戒断综合征后最初24小时内使用>50%的总地西泮用量。
- POST组采用24小时负荷期递增剂量苯二氮䓬和苯巴比妥、72小时减量期后停药的限时方案。
- POST组接受集中治疗比例更高(73.7% vs 51.3%,p=0.03),住院时间(9.8天 vs 14.0天,p=0.03)和ICU时间(4.4天 vs 7.4天,p=0.03)显著缩短。
适用人群与场景
- 纳入重度酒精戒断综合征患者;PRE组2015年1月至11月入院,POST组2016年4月至2017年3月入院。
- 重度酒精戒断综合征定义为需要地西泮剂量>30 mg。
诊断标准与关键阈值
- 重度酒精戒断综合征:需要地西泮剂量>30 mg。
- 集中治疗:在识别酒精戒断综合征后最初24小时内使用>50%的总地西泮用量。
处置流程与药物剂量
- PRE组:按RASS给予症状触发、递增剂量的地西泮和苯巴比妥。
- POST组:24小时负荷期内给予递增剂量的苯二氮䓬和苯巴比妥,72小时减量期后全部停药;使用SHOT量表辅助RASS评估非激越症状并指导额外地西泮剂量。
研究设计与关键结果
- 研究类型为前后对照队列研究,共532例患者使用酒精戒断综合征方案,其中113例发生重度酒精戒断综合征(PRE组n=75,POST组n=38)。
- PRE组与POST组在年龄、性别、酒精戒断综合征病史和疾病严重程度上匹配。
- POST组接受集中治疗的比例为73.7%,PRE组为51.3%(p=0.03)。
- POST组住院时间9.8天 vs PRE组14.0天(p=0.03),ICU时间4.4天 vs 7.4天(p=0.03)。
证据类型、等级与局限
- 证据类型:前后对照队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,重度酒精戒断综合征的早期集中管理与ICU和住院时间缩短相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Objective: Current evidence supports symptom-triggered therapy for alcohol withdrawal syndrome (AWS). Early, escalating therapy with benzodiazepines (BZD) appears to decrease ICU length of stay (LOS); however, the effect on hospital LOS remains unknown. The hypothesis of this study is that focused BZD treatment in the first 24 h will decrease hospital LOS. Design: Pre-post cohort study. Setting: Academic medical center. Patients: This study included patients with severe AWS. The pre-intervention cohort (PRE) was admitted between January and November 2015. The post-intervention cohort (POST) was admitted between April 2016 and March 2017. Severe AWS was defined as patients requiring diazepam doses of >30 mg. Focused treatment was defined as >50% of total diazepam usage within the first 24 h of recognition of AWS. Intervention: In the PRE group, patients received symptom-triggered, escalating doses of diazepam and phenobarbital based on their Richmond Agitation-Sedation Scale (RASS). In the POST group, patients received a revised, time-limited course of therapy: escalating doses of BZD and phenobarbital were given during a 24-h loading phase, and all therapy was discontinued after a 72-h tapering phase. The SHOT scale was used as an adjunct to RASS to assess non-agitation symptoms of AWS and guide additional diazepam doses. Measurements and main results: The primary outcome was hospital LOS; secondary outcomes included ICU LOS, BZD use, and ventilator-free days. Five hundred thirty-two patients were treated using the AWS protocol; 113 experienced severe AWS. The PRE (n = 75) and POST (n = 38) groups were evenly matched in age, sex, history of AWS, and severity of illness. There was a substantial difference in POST patients who received focused treatment (51.3% vs. 73.7%, p = .03). The POST group had a significant decrease in hospital LOS (14.0 vs. 9.8 days, p = .03) and ICU LOS (7.4 vs. 4.4 days, p = .03). Conclusion: Early, focused management of severe AWS was associated with a decrease in ICU and hospital LOS.
参考来源
- Lee JA, Duby JJ, Cocanour CS, et al. Effect of early and focused benzodiazepine therapy on length of stay in severe alcohol withdrawal syndrome. Clin Toxicol (Phila). 2019. PMID: 30729859. doi:10.1080/15563650.2018.1542701
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。